Browsing Tag
Blueprint Medicines
7 posts
Cogent Biosciences (NASDAQ: COGT) slips after hours as insider sales prompt investor scrutiny
Cogent Biosciences stock fell after hours on insider sales by multiple executives. Find out why it matters now and what it means for investors going forward.
Biggest pharma deals of 2025: How $70bn in M&A reshaped global drug strategy
Find out how Johnson & Johnson, Novartis, and Sanofi led the $70B pharma M&A wave in 2025, reshaping drug development strategy and investor confidence.
Sanofi to acquire Vicebio in $1.15bn deal to expand RSV and hMPV vaccine pipeline
Sanofi doubles down on vaccines and rare immunology with Vicebio and Blueprint acquisitions. Find out how these deals could reshape its growth strategy.
Sanofi’s $9.5bn buyout of Blueprint Medicines signals high-stakes immunology expansion
Sanofi’s $9.5B Blueprint Medicines acquisition strengthens its rare disease pipeline with Ayvakit and signals deeper investment in immunology.
CHMP adopts positive opinion for avapritinib for PDGFRA D842V mutant GIST
US precision therapy company Blueprint Medicines said that the Committee for Medicinal Products for Human Use (CHMP) of…
Blueprint Medicines strikes $1.7bn worth deal with Roche for pralsetinib
Swiss pharma giant Roche and US precision therapy company Blueprint Medicines have entered into a worldwide licensing and…
FDA rejects Blueprint’s NDA for AYVAKIT for treatment of fourth-line GIST
Blueprint Medicines said that the US Food and Drug Administration (FDA) has rejected its new drug application (NDA)…